Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Clin Cancer Res. 2016 Jan 18;22(11):2791–2801. doi: 10.1158/1078-0432.CCR-15-1511

Figure 4. Knockdown of NDUFA4L2 causes metabolic alterations.

Figure 4

(A) Comparison of the levels of the TCA cycle intermediates citrate/isocitrate, α-ketoglutarate, succinate, and oxaloacetate in parental RCC4 cells and cells infected with the indicated shRNA constructs for 24 hours followed by puromycin for 96 hours. (B) Comparison of the levels of the pentose phosphate pathway intermediates ribose 5-phosphate, sedoheptulose 7-phosphate, glyceraldehyde 3-phosphate, and fructose 6-phosphate in parental RCC4 cells and cells infected with the indicated shRNA constructs for 24 hours followed by puromycin for 96 hours. (C) Schematic overview of the changes in the TCA cycle and pentose phosphate pathway upon treatment with shNDUFA4L2.1 in RCC4 cells. Arrows next to metabolites indicate that the metabolite levels are changed in shNDUFA4L2.1 treated cells compared to parental and shCTL treated cells. Metabolomics analysis was performed on samples in triplicate (n=3 for each group) and data are graphed as the mean ± SEM. ** p < 0.01; **** p < 0.0001.